Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study

BackgroundConcurrent programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors with sequential chemoradiotherapy (SCRT) have been reported in only a limited number of studies involving patients with unresectable stage III non-small-cell lung cancer (NSCLC). A retrospective study was...

Full description

Bibliographic Details
Main Authors: Shi Tang, Xiaofeng Cong, Dan Zheng, Chen Chen, Zengguang Liu, Jie Gao, Huimin Zhang, Youhao Zhang, Ziling Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
chemoradiotherapy
PD1/PDL1 inhibitor
sintilimab
safety
retrospective study
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1129989/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1129989/full

Similar Items